Valentini, D.; Cotugno, N.; Scoppola, V.; Di Camillo, C.; Colagrossi, L.; Manno, E.C.; Perno, C.F.; Russo, C.; Palma, P.; Rossi, P.;
et al. Safety and Long-Term Immunogenicity of BNT162b2 Vaccine in Individuals with Down Syndrome. J. Clin. Med. 2022, 11, 694.
https://doi.org/10.3390/jcm11030694
AMA Style
Valentini D, Cotugno N, Scoppola V, Di Camillo C, Colagrossi L, Manno EC, Perno CF, Russo C, Palma P, Rossi P,
et al. Safety and Long-Term Immunogenicity of BNT162b2 Vaccine in Individuals with Down Syndrome. Journal of Clinical Medicine. 2022; 11(3):694.
https://doi.org/10.3390/jcm11030694
Chicago/Turabian Style
Valentini, Diletta, Nicola Cotugno, Vittorio Scoppola, Chiara Di Camillo, Luna Colagrossi, Emma Concetta Manno, Carlo Federico Perno, Cristina Russo, Paolo Palma, Paolo Rossi,
and et al. 2022. "Safety and Long-Term Immunogenicity of BNT162b2 Vaccine in Individuals with Down Syndrome" Journal of Clinical Medicine 11, no. 3: 694.
https://doi.org/10.3390/jcm11030694
APA Style
Valentini, D., Cotugno, N., Scoppola, V., Di Camillo, C., Colagrossi, L., Manno, E. C., Perno, C. F., Russo, C., Palma, P., Rossi, P., & Villani, A.
(2022). Safety and Long-Term Immunogenicity of BNT162b2 Vaccine in Individuals with Down Syndrome. Journal of Clinical Medicine, 11(3), 694.
https://doi.org/10.3390/jcm11030694
